Driehaus Capital Management LLC Sells 25,818 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Driehaus Capital Management LLC cut its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 22.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,496 shares of the biotechnology company's stock after selling 25,818 shares during the quarter. Driehaus Capital Management LLC owned about 0.15% of Ascendis Pharma A/S worth $12,183,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently modified their holdings of ASND. Wilmington Savings Fund Society FSB purchased a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at $30,000. Jones Financial Companies Lllp grew its position in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 197 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 328 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 214 shares during the last quarter. Finally, Quarry LP purchased a new position in shares of Ascendis Pharma A/S in the fourth quarter worth approximately $96,000.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $200.00 target price on shares of Ascendis Pharma A/S in a research report on Monday. Royal Bank of Canada lifted their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. JPMorgan Chase & Co. raised their price target on Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a report on Friday, May 2nd. Morgan Stanley raised shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $180.00 to $250.00 in a research note on Monday, May 5th. Finally, Wedbush lifted their price target on Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of "Moderate Buy" and an average price target of $216.07.

Ascendis Pharma A/S Stock Up 4.6%

ASND traded up $7.09 on Tuesday, reaching $161.52. 495,599 shares of the company traded hands, compared to its average volume of 500,815. The company has a market cap of $9.85 billion, a P/E ratio of -22.75 and a beta of 0.41. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $183.00. The firm has a fifty day simple moving average of $156.09 and a two-hundred day simple moving average of $141.71.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analysts' expectations of $98.56 million. On average, equities analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.